GHENT, Belgium, Feb. 18, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its full year results for 2015 on Thursday 25 February 2016 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2015 will be presented, followed by a Q&A session. This event will be held on Thursday 25 February 2016 at 4.00 pm CET/10.00 am EST.
The conference call will be webcast live and may be accessed by clicking here. If you would like to participate in the Q&A session, please dial +32(0)2 404 06 62 and use confirmation code 4640794. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under http://www.ablynx.com/news/events-presentations/.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact Ablynx: Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
press release in pd format http://hugin.info/137912/R/1986956/729119.pdf
HUG#1986956


Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
Google Secures Pentagon AI Deal for Classified Projects
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 



